Immuneering (NASDAQ:IMRX) Given Buy Rating at Chardan Capital

Chardan Capital restated their buy rating on shares of Immuneering (NASDAQ:IMRX) in a report issued on Wednesday,Benzinga reports. Chardan Capital currently has a $13.00 price target on the stock.

Separately, Needham & Company LLC reissued a “buy” rating and issued a $15.00 price objective on shares of Immuneering in a research note on Thursday, November 14th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $12.80.

Immuneering Price Performance

Shares of IMRX stock opened at $2.04 on Wednesday. The company has a market capitalization of $63.34 million, a P/E ratio of -1.04 and a beta of -0.40. The company’s 50-day simple moving average is $2.21 and its two-hundred day simple moving average is $1.62. Immuneering has a one year low of $1.00 and a one year high of $8.89.

Institutional Trading of Immuneering

A number of hedge funds have recently bought and sold shares of IMRX. Vontobel Holding Ltd. purchased a new position in Immuneering in the third quarter valued at about $25,000. Corsair Capital Management L.P. bought a new stake in shares of Immuneering in the 3rd quarter valued at about $25,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Immuneering in the 2nd quarter worth approximately $44,000. XTX Topco Ltd lifted its holdings in shares of Immuneering by 37.3% during the 2nd quarter. XTX Topco Ltd now owns 34,159 shares of the company’s stock valued at $44,000 after purchasing an additional 9,274 shares during the last quarter. Finally, Acadian Asset Management LLC acquired a new stake in Immuneering in the second quarter worth about $67,000. Hedge funds and other institutional investors own 67.65% of the company’s stock.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.